Sidley represented Bio-Techne Corporation (NASDAQ: TECH), a nearly 50-year-old leading provider of life science tools, analytical technologies, and consumables, in its acquisition by Merck KGaA, a global science and technology company headquartered in Darmstadt, Germany. Merck, subject to customary closing conditions, will acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion.
The Sidley team was led by Beth E. Berg, Michael A. Gordon, and Sally Wagner Partin (M&A and Private Equity), and included Alex Enion, Leila Malek, Jordan M. Lemoine, Jack N. Cadden, Lynzai N. Cutler, Eduardo K. Cavalieri, Natalie Knowles, and James F. Lochrie (M&A and Private Equity); Ken Daly, Jim Lowe, Mary K. Marks, Sarah Scheinman, Fiona Shajko, Ignacio Montaño Díaz, and Chelsey Miao (Antitrust and Competition); Donielle McCutcheon and Trevor L. Wear (Healthcare); Torrey Cope, Josefine Sommer, and Emily Marden (FDA Regulatory); Sven De Knop, Jen Fernandez, James Mendenhall, Maryanne Kamau, Ben Vallimarescu, and Laura Verbeken (Global Arbitration, Trade and Advocacy); Corey Perry, Elizabeth T. Burns, Alexandra M. Peterson, and Liz Eastlund (Employee Benefits and Executive Compensation); Peter McCorkell, Teresa L. Reuter, and Alex Down (Labor, Employment and Immigration); Christian Brause and Greg Featherman (Tax); Kayla M. West (Capital Markets); Colleen T. Brown and Sasha Hondagneu-Messner (Privacy and Cybersecurity); Joshua T. Hofheimer and Zach Johnston (Technology and Life Sciences Transactions); and Elizabeth K. McCloy and Brandon Bryer (Real Estate).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
